2024
BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE
Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.Peer-Reviewed Original ResearchNon-small cell lung cancerLeptomeningeal diseaseCentral nervous systemLeptomeningeal metastasesParenchymal metastasesCerebrospinal fluidTumor cellsTyrosine kinase inhibitor treatmentCell lung cancerKinase inhibitor treatmentCerebrospinal fluid of patientsCell linesCerebral lateral ventriclesIntra-arterial injectionTGF-b signalingIn vivo passageIntraparenchymal diseaseMechanisms of progressionTumor microenvironmentMultiplex immunofluorescenceAggressive treatmentLeptomeningeal infiltrationPerivascular invasionIntraparenchymal metastasesMurine modelReal-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.
Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.Peer-Reviewed Original ResearchNon-small cell lung cancerDiagnosis of LMNational Comprehensive Cancer NetworkLeptomeningeal metastasesTumor cell assayPositive CTCsCerebrospinal fluidData cutoffOverall survivalNeurological symptomsAssessment of circulating tumor DNASensitivity of tumor cell detectionCTC assayManagement of leptomeningeal metastasisTime of data cutoffDiagnosis of leptomeningeal metastasisAssociated with longer survivalMedian overall survivalOmmaya reservoir placementEnumeration of circulating tumor cellsNegative cytology resultsCell lung cancerEffective treatment optionProgressive neurological symptomsInitiation of treatment
2021
BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER
Kumthekar P, Blouw B, Mayer J, Fisher D, Dugan M, Azadi A, Blondin N. BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology 2021, 23: vi10-vi10. PMCID: PMC8598619, DOI: 10.1093/neuonc/noab196.036.Peer-Reviewed Original ResearchCSF tumor cellsLeptomeningeal diseaseBreast cancer patientsIntrathecal treatmentTumor cellsCase seriesOmmaya reservoirCancer patientsCerebrospinal fluidLarge prospective clinical trialsSmilow Cancer HospitalYale-New HavenMetastatic breast cancerProspective clinical trialsBarrow Neurological InstituteIntrathecal therapyTumor cell detectionFourth patientCancer HospitalTumor InstituteClinical managementClinical trialsBreast cancerTreatment responsePatients